Cell Therapy News Volume 26.02 | Feb 10 2025

    0
    58







    2025-02-10 | CTN 26.02


    Cell Therapy News by STEMCELL Technologies
    Vol. 26.02 – 10 February, 2025
    TOP STORY

    HIV Immune Evasin Nef Enhances Allogeneic CAR T Cell Potency

    Researchers found that viral evasins that partially reduced HLA class I expression could shelter CAR T cells from mismatched CD8+ T cells without triggering ‘missing-self’ rejection by NK cells.
    [Nature]

    Abstract
    PUBLICATIONSListed by the impact factor of the journal

    A Neoantigen Vaccine Generates Antitumor Immunity in Renal Cell Carcinoma

    Investigators conducted a Phase I trial to test a neoantigen-targeting personalized cancer vaccine in patients with high-risk, fully resected clear cell renal cell carcinoma with or without ipilimumab administered adjacent to the vaccine.
    [Nature]

    Full ArticlePress Release

    AAV Capsid Prioritization in Normal and Steatotic Human Livers Maintained by Machine Perfusion

    To predict adeno-associated virus (AAV) capsid performance under near-clinical conditions, scientists established side-by-side comparison at single-cell resolution in human livers maintained by normothermic machine perfusion.
    [Nature Biotechnology]

    Full Article

    Randomizing the Human Genome by Engineering Recombination between Repeat Elements

    The authors leveraged prime editing of the high-copy-number, long interspersed nuclear element-1 retrotransposon to engineer incorporation of thousands of Cre-recombinase sites into the genomes of two human cell lines.
    [Science]

    AbstractPress ReleaseGraphical Abstract

    Results from First-in-Human Phase I Study of a Novel CD19-1XX Chimeric Antigen Receptor with Calibrated Signaling in Large B-Cell Lymphoma

    In this first-in-human, Phase I, dose escalation, and expansion clinical trial, patients with relapsed or refractory large B-cell lymphoma received 19(T2)28z-1XX CAR T cells at four dose levels.
    [Journal of Clinical Oncology]

    Abstract

    Nature-Inspired Platform Nanotechnology for RNA Delivery to Myeloid Cells and their Bone Marrow Progenitors

    Researchers presented a nanotechnology platform based on natural lipoproteins, designed for delivering small interfering RNA, antisense oligonucleotides, and messenger RNA to myeloid cells and hematopoietic stem and progenitor cells in the bone marrow.
    [Nature Nanotechnology]

    Full Article

    FLASH Radiation Reprograms Lipid Metabolism and Macrophage Immunity and Sensitizes Medulloblastoma to CAR T Cell Therapy

    Using a genetically engineered mouse model of medulloblastoma, investigators showed that FLASH radiation stimulated proinflammatory polarization in tumor macrophages.
    [Nature Cancer]

    Abstract

    Correcting a Pathogenic Mitochondrial DNA Mutation by Base Editing in Mice

    Researchers used a mitochondrial DddA-derived cytosine base editor to correct a mutation in the mitochondrial DNA encoding a mitochondrial transfer RNA alanine.
    [Science Translational Medicine]

    Abstract

    A Universal and Wide-Range Cytosine Base Editor via Domain-Inlaid and Fidelity-Optimized CRISPR-FrCas9

    A series of iteratively improved cytosine base editors were constructed using the FrCas9 nickase with the unique protospacer adjacent motif palindromic structure to alleviate these challenges.
    [Nature Communications]

    Full Article

    Vaccine-Induced T Cell Receptor T Cell Therapy Targeting a Glioblastoma Stemness Antigen

    Researchers identified a therapeutic HLA-A*02-restricted protein tyrosine phosphatase receptor type Z1-reactive T cell receptor retrieved from a vaccinated glioblastoma patient.
    [Nature Communications]

    Full Article

    Targeting the TRIM21-PD-1 Axis Potentiates Immune Checkpoint Blockade and CAR T Cell Therapy

    Scientists reported that TRIM21 impaired CD8+ T cell activation and anti-tumor immunity. Mechanistically, TRIM21 catalyzed the K63-linked ubiquitination on PD-1 at K233, leading to stabilization of PD-1 through antagonizing its K48-linked ubiquitination and degradation.
    [Molecular Therapy]

    AbstractGraphical Abstract

    Phase I Clinical Trial of B Cell Maturation Antigen (BCMA) NEX-T® Chimeric Antigen Receptor (CAR) T Cell Therapy CC-98633/BMS-986354 in Participants with Triple-Class Exposed Multiple Myeloma

    Researchers conducted a Phase I clinical trial of BMS-986354, an autologous BCMA CAR T manufactured using an optimized NEX-T® process, in participants with triple-class exposed, refractory multiple myeloma.
    [Leukemia]

    Full Article

    Non-Invasive Detection of Allele-Specific CRISPR-SaCas9-KKH Disruption of TOR1A DYT1 Allele in a Xenograft Mouse Model

    The authors demonstrated a gene editing approach that selectively targeted the dominant 3-base pair deletion in the TOR1A DYT1 allele while safeguarding the wild-type TOR1A allele.
    [Molecular Therapy – Nucleic Acids]

    AbstractFull ArticleGraphical Abstract
    REVIEWS

    Novel Strategies to Manage CAR-T Cell Toxicity

    Investigators summarize the current management of cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, and review T cell- and myeloid cell-intrinsic druggable targets and cellular engineering strategies to develop safer CAR-T cells.
    [Nature Reviews Drug Discovery]

    Abstract

    Mesenchymal Stromal Cell Therapy: Progress to Date and Future Outlook

    Scientists provide background on the history and potential therapeutic value of mesenchymal stromal/stem cells (MSC), an overview of MSC products with regulatory approval, and a summary of registered MSC trials.
    [Molecular Therapy]

    AbstractGraphical Abstract

    Harnessing the Power of TCR-T Cell Therapy: A New Era in Cancer Immunotherapy

    The authors discuss the FDA’s approval of afami-cel, a first-in-class gene-modified autologous T cell therapy, for the treatment of specific solid tumor indications.
    [Cancer Letters]

    Abstract
    INDUSTRY AND POLICY NEWS

    Bristol Myers Angles Breyanzi for Another Blood Cancer as It Works to Close Gilead’s CAR-T Lead

    With another trial win, Bristol Myers Squibb is touting Breyanzi as the CD19-directed CAR-T therapy with positive readouts in most cancer types. The latest readout positions Breyanzi for a potential foray into marginal zone lymphoma, for which none of the existing CAR-T therapies are approved by the FDA.
    [Fierce Pharma]

    Press Release
    FEATURED EVENT

    Advanced Therapies UK

    March 18-19, 2025
    London, England, United Kingdom

    > See All Events

    JOB OPPORTUNITIES

    Physician – Pediatric Stem Cell Transplant and Cellular Therapy

    University of Wisconsin – Madison, Wisconsin, United States

    Postdoctoral Position – T Cell Engineering

    Stanford – Palo Alto, California, United States

    Scientist- Preclinical Design and Development Core

    St. Jude Children’s Research Hospital – Memphis, Tennessee, United States

    Scientist/Associate Scientist – Personalized Genomic Therapeutics

    St. Jude Children’s Research Hospital – Memphis, Tennessee, United States

    Postdoctoral Position – Regulatory T Cell Therapy for Type 1 Diabetes

    French National Institute for Health Research (INSERM) – Paris, France

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2